Form 4: TG Therapeutics Director Gifts Shares to Children

TG Therapeutics Director Laurence N. Charney gifted a total of 43,197 shares of common stock to his children in late January 2026.

Summary

• Laurence N. Charney, a Director of TG Therapeutics, Inc. (TGTX), reported two transactions involving the disposition of common stock.
• On January 28, 2026, Charney gifted 30,000 shares of common stock.
• On January 29, 2026, Charney gifted an additional 13,197 shares of common stock.
• These transactions represent bona fide gifts to his children, with Charney retaining no beneficial ownership or pecuniary interest over the gifted shares.
• Following these transactions, Charney beneficially owns 179,690 shares of common stock, which includes restricted common stock vesting over various time periods.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. Insider gifts are typically for personal estate planning and do not inherently signal positive or negative sentiment towards the company's operational performance or future prospects.

Future Outlook

NA

Management Comments

• Represents a bona fide gift by the Reporting Person to the Reporting Person's children.
• The Reporting Person does not retain any beneficial ownership or pecuniary interest over the shares of the Company's Common Stock after effecting the transaction.

Industry Context

StockSavvy.ai notes that insider gifting, while reducing direct ownership, is a common estate planning strategy and typically does not reflect a change in the insider's view of the company's prospects, unlike open market sales.

Related Party Transactions

• Director Laurence N. Charney gifted 43,197 shares of common stock to his children.

Stakeholder Impact

• Shareholders: The total number of outstanding shares remains unchanged, but the beneficial ownership of a director has decreased, shifting ownership to family members.

Key Dates

Recommendation

This Form 4 filing reports a director's gift of shares, which is a personal estate planning event rather than a reflection of the company's operational performance or strategic direction. It does not provide new information that would warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

TG Therapeutics, TGTX, Form 4, Insider Transaction, Stock Gift, Laurence N. Charney, Director, Common Stock